During the past few decades, numerous small-molecule tyrosine kinase inhibitors (TKIs) were widely approved as targeted therapy in NSCLC, including EGFR-TKIs and ALK-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.